Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epoetin alfa RB
- Development stage
- Approved
- Lead developer
- Amgen
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Epoetin alfa RB refers to Epoetin alfa manufactured using Roller-Bottle Technology. Epoetin alfa is a recombinant human erythropoietin (rHuEPO), a glycoprotein hormone that acts as an erythropoiesis-stimulating agent. It is primarily used to treat anemia by stimulating the production of red blood cells in the bone marrow. Its main indications include anemia associated with chronic kidney disease (CKD), chemotherapy-induced anemia in cancer patients, and anemia in HIV-infected patients treated with zidovudine. The drug works by binding to and activating erythropoietin receptors on erythroid progenitor cells, promoting their proliferation, differentiation, and survival, thereby increasing red blood cell count and hemoglobin levels. Amgen is a key developer of epoetin alfa and sponsored clinical trials for Epoetin alfa RB.
- Brand names
- EpogenProcritRetacritBinocritNeorecormonMirceraEprex
- Other names
- Epoetin alfa Manufactured by Roller-Bottle Technology
02
Targets
Beyond the preview
Go deeper on Epoetin alfa RB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epoetin alfa RB.